Rx Item-Fenofibrate 134MG 20 CAP-Cool Store- by American Health Packaging USA

LOFIBRA- fenofibrate tablet, film coated
Teva Select Brands

1 INDICATIONS AND USAGE

1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia
LOFIBRA� is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

1.2 Severe Hypertriglyceridemia


LOFIBRA� is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.

Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.

1.3 Important Limitations of Use
Fenofibrate at a dose equivalent to 145 mg of LOFIBRA� was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1)].

2 DOSAGE AND ADMINISTRATION

2.1 General Considerations
Patients should be placed on an appropriate lipid-lowering diet before receiving LOFIBRA� , and should continue this diet during treatment with LOFIBRA�. LOFIBRA� tablets can be given without regard to meals.

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.

Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of LOFIBRA� if lipid levels fall significantly below the targeted range.

Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 160 mg once daily.

Rx Item-Fenofibrate 134MG 20 CAP-Cool St
Item No. RX351619, 351619, NDC No.: 68084-0835-32, 68084-835-32, 6808483532, 68084083532, 0835-32, 083532 UPC No. 3-68084-83532-2, 368084-835322, 368084835322

Rx Item-Fenofibrate 134MG 20 CAP-Cool St
Item No. RX351619, 351619, NDC No.: 68084-0835-32, 68084-835-32, 6808483532, 68084083532, 0835-32, 083532 UPC No. 3-68084-83532-2, 368084-835322, 368084835322

Rx Item-Fenofibrate 134MG 20 CAP-Cool St
Rx items can only be ordered by a valid licence holder in scope of practice by-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physica